What this test measures
Alpha-fetoprotein (AFP) is a glycoprotein produced in large amounts by the fetal yolk sac and liver during pregnancy. In adults it falls to very low levels (< 10 ng/mL). The test measures serum AFP by immunoassay (chemiluminescence or ECLIA).
AFP is used in two very different contexts: • As a tumor marker — for hepatocellular carcinoma (HCC) surveillance and treatment monitoring, and for germ cell tumours (testicular, ovarian non-seminomatous). • As part of maternal screening — abnormally low or high AFP in the second trimester suggests fetal chromosomal or structural abnormalities (see Triple / Quadruple Test).
Why it matters
India has a rising burden of hepatocellular carcinoma driven by chronic hepatitis B, hepatitis C, alcohol, and the growing epidemic of metabolic-associated fatty liver disease (MAFLD). AFP combined with ultrasound is the standard surveillance approach for patients with cirrhosis or chronic hepatitis B — early detection of HCC at a curable stage is the goal.
However, AFP is NOT a screening test for the general asymptomatic population. NCCN and AASLD guidelines explicitly do not recommend AFP in low-risk individuals — false positives lead to anxiety, unnecessary imaging, and overtreatment. For at-risk individuals (cirrhosis, chronic HBV), 6-monthly AFP + ultrasound is the recommended surveillance protocol. For germ cell tumours, AFP is used at diagnosis, during treatment, and in long-term surveillance for recurrence.
How to prepare
No fasting required. A standard venous blood sample is collected. Mention any pregnancy (results need pregnancy-adjusted interpretation), liver disease, hepatitis B/C infection, alcohol use, or testicular / ovarian tumour history. Note any recent biotin supplements (high-dose biotin can interfere with some immunoassays).
Markers & reference ranges
Reference ranges below are typical adult values. Your lab's reported range may differ slightly based on the assay platform and patient demographics — always read your report against the range printed on it.
| Marker | Normal range | If low | If high |
|---|---|---|---|
| Serum AFP (ng/mL)[1][2][3] | Non-pregnant adults: < 10 ng/mL | Low / normal AFP in an at-risk individual does not exclude HCC — combine with ultrasound. | 10–200 ng/mL: nonspecific elevation — consider hepatitis flare, cirrhosis, pregnancy. 200–500 ng/mL in a cirrhotic patient: suspicious for HCC. > 500 ng/mL: strong suspicion of HCC; CT / MRI imaging warranted. AFP also rises in germ cell tumours (yolk-sac, embryonal carcinoma) — values can be very high (thousands). |
AFP cutoffs and interpretation in HCC surveillance
| AFP (ng/mL) | Sensitivity for HCC | Specificity | Typical interpretation |
|---|---|---|---|
| < 10 | Reassuring (but does not exclude) | — | Continue surveillance |
| 10 – 20 | Low sensitivity | Low specificity | Repeat in 3 months; consider hepatitis flare |
| 20 – 200 | Higher concern | Variable | Triple-phase CT or MRI of liver |
| 200 – 500 | Strong concern | Higher | Image immediately; LI-RADS scoring |
| > 500 (cirrhotic) | Near-diagnostic for HCC | Very high | Treat as HCC after imaging confirmation |
Frequently asked questions
Should I get an AFP test as a routine cancer screen?
No. AFP is NOT recommended for screening the asymptomatic general population. NCCN, AASLD, and most major guidelines explicitly avoid AFP in low-risk individuals — the false-positive rate causes unnecessary anxiety, scans, and biopsies. AFP is for surveillance in known high-risk patients (cirrhosis, chronic HBV) and for monitoring known germ cell tumours.
When is AFP genuinely useful?
In patients with cirrhosis or chronic hepatitis B for HCC surveillance (with ultrasound every 6 months). In confirmed germ cell tumours (testicular non-seminomatous, ovarian) for monitoring response and recurrence. In second-trimester pregnancy as part of the triple / quadruple test for neural tube defects and Down syndrome screening.
My AFP is slightly elevated — do I have cancer?
Probably not. AFP often rises modestly (10–100 ng/mL) in chronic hepatitis flares, cirrhosis without HCC, pregnancy, and even normal liver regeneration. Persistently rising AFP in an at-risk patient is more concerning than a single mildly elevated value.
How often should at-risk patients get AFP and ultrasound?
Every 6 months for patients with cirrhosis (any cause) and certain chronic HBV patients (without cirrhosis but high-risk: family history, age > 40, high viral load).
Can AFP detect early-stage HCC?
Not always. AFP has limited sensitivity for small HCC (sensitivity ~60% at the 20 ng/mL cutoff). Ultrasound complements it. Newer markers (AFP-L3, DCP / PIVKA-II) and GALAD score improve detection.
How long does the report take?
Most NABL labs deliver AFP results in 24 hours.
Does fasting affect AFP?
No fasting is required.
Related Oncology / Tumor Markers tests
Tests commonly ordered alongside ALPHA FETO PROTEIN (AFP), or that help interpret an unexpected result.
Sources & references
- NCCN — Hepatocellular Carcinoma Guidelines · accessed 2026-05-30T00:00:00.000Z
- American Cancer Society — Tumor Markers · accessed 2026-05-30T00:00:00.000Z
- NCBI StatPearls — Alpha Fetoprotein · accessed 2026-05-30T00:00:00.000Z
- NIH MedlinePlus — AFP Tumor Marker · accessed 2026-05-30T00:00:00.000Z
Book with Zelnoo
Get your ALPHA FETO PROTEIN (AFP) test done at home — transparent prices, NABL-accredited labs.
Zelnoo lets you compare diagnostic test prices across NABL-accredited labs in Mumbai & Thane, book a free home phlebotomist visit, and receive digital reports in 24–48 hours into a consent-first report vault. No subscriptions, no membership fees — pay only for the test you book.
Book ALPHA FETO PROTEIN (AFP) now